Blood-Matching Goes Genetic

  title={Blood-Matching Goes Genetic},
  author={Elizabeth A. Quill},
  pages={1478 - 1479}
Hoping to prevent adverse transfusion reactions and save lives, European researchers are lobbying to replace serology-based blood typing with matching based on DNA tests. 
Technologies involved in molecular blood group genotyping
The haemagglutination test provides only indirect indications of risk or severity of haemolytic disease of the new born and nucleic acid‐based technologies have been used in immunohematology reference laboratories. Expand
Development of a Blood Antigen Molecular Profiling Panel using Genotyping Technologies for Patients Requiring Frequent Transfusions
Molecular profiling of blood donors for minor red blood cell and platelet antigens will give blood banks instant access to many different compatible donors through the set-up of a centralized data storage system. Expand
Overcoming methodical limits of standard RHD genotyping by next‐generation sequencing
This pilot study compared a newly established next‐generation sequencing approach based on pyrosequencing to determine rare and unknown RHD genotypes by sequence‐based typing by standard Sanger sequencing. Expand
Molecular genotyping in transfusion medicine.
SNPs account for much of human genome diversity, and the ability to link SNPs to disease or disease risk, and even to individual variation in drug responses, makes SNP profiling a technology likely to contribute to fulfilling the promise of personalized medicine. Expand
It's time to phase in RHD genotyping for patients with a serologic weak D phenotype
Current RhD typing practice, together with contemporary obstetrical practices for administration of antepartum and postpartum RhIG, is estimated to be 98.4 to 99 percent successful in preventing RhD alloimmunization and RhD hemolytic disease of the fetus/newborn. Expand
Genotyping for human platelet alloantigen polymorphisms: applications in the diagnosis of alloimmune platelet disorders.
  • B. Curtis
  • Medicine
  • Seminars in thrombosis and hemostasis
  • 2008
Platelet genotyping is a valuable tool in confirming platelet antigen specificities of alloantibodies detected in patient sera to complement the clinical history in the diagnosis ofalloimmune platelet disorders such as fetal and neonatal alloimmune thrombocytopenia (FNAIT), posttransfusion purpura, and multiplatelet transfusion refractoriness. Expand
Molecular Diagnostics in Transfusion Medicine: In Capillary, on a Chip, in Silico, or in Flight?
The special focus of this paper is a relative new technique: SNP genotyping by MALDI-TOF MS analysis, which has the potential for automation, high throughput and cost effectiveness. Expand
Extended blood group molecular typing and next-generation sequencing.
Various target enrichment NGS approaches are described that can be used to develop an extended blood group genotyping assay system, able to assess genetic variations that cannot be achieved by traditional Sanger sequencing or othergenotyping platforms. Expand
Blood group genotyping: from patient to high‐throughput donor screening
Genotyping of blood donors will be extremely useful to obtain donor blood with rare phenotypes, for example lacking a high‐frequency antigen, and to obtain a fully typed donor database to be used for a better matching between recipient and donor to prevent adverse transfusion reactions. Expand
Elucidating Genetic and Biochemical Aspects of the P1 and Sda Carbohydrate Histo-Blood Group Antigens
Human histo-blood groups are inherited polymorphic variants that occur in the molecular structures on the human red blood cell (RBC) surface. Introducing foreign RBCs into a recipient lacking anExpand